Paul Rennert
@pdrworld.bsky.social
Biotech exec, pro drug developer. Amateur everything else: COOKING, ferments, preserving, charcuterie, fishing, gardening, weightlifting, BIRDER, photography, physics, literature, writer, history, DAD
reminds me to share a landscape peak into advanced therapies - CAR-T and bispecifics - in the autoimmune and inflammation space
July 22, 2025 at 11:57 AM
reminds me to share a landscape peak into advanced therapies - CAR-T and bispecifics - in the autoimmune and inflammation space
for #biotech and advanced therapeutics followers, a cool paper here: doi.org/10.1016/j.me...
July 22, 2025 at 11:54 AM
for #biotech and advanced therapeutics followers, a cool paper here: doi.org/10.1016/j.me...
Concentra goes shopping again, adds CARGO to its market basket
finance.yahoo.com/news/cargo-t...
Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
finance.yahoo.com/news/cargo-t...
Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
July 8, 2025 at 12:13 PM
Concentra goes shopping again, adds CARGO to its market basket
finance.yahoo.com/news/cargo-t...
Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
finance.yahoo.com/news/cargo-t...
Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
HER3 activation and overexpression in cancers makes this antigen an attractive target for antibody therapeutics ---> a rapidly expanding drug development landscape has emerged sugarconebiotech.com/insights
July 7, 2025 at 11:39 AM
HER3 activation and overexpression in cancers makes this antigen an attractive target for antibody therapeutics ---> a rapidly expanding drug development landscape has emerged sugarconebiotech.com/insights
and here's a bispecific landscape update from the analysts at sugarconebiotech.com
April 17, 2025 at 5:19 PM
and here's a bispecific landscape update from the analysts at sugarconebiotech.com
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
April 8, 2025 at 8:18 PM
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
the ivonescimab clinical data have published in @thelancet.bsky.social
www.thelancet.com/journals/lan...
and they added some great commentary
www.thelancet.com/journals/lan...
and they added some great commentary
March 13, 2025 at 3:51 PM
the ivonescimab clinical data have published in @thelancet.bsky.social
www.thelancet.com/journals/lan...
and they added some great commentary
www.thelancet.com/journals/lan...
and they added some great commentary
how to survive reviewing those papers you promised to review.
#protip for #biotech and #academics
archive.org/details/ttb2...
#protip for #biotech and #academics
archive.org/details/ttb2...
March 7, 2025 at 1:30 PM
how to survive reviewing those papers you promised to review.
#protip for #biotech and #academics
archive.org/details/ttb2...
#protip for #biotech and #academics
archive.org/details/ttb2...
A bit more #bioblue #biotech #oncology news from aletabiotherapeutics.com - we've invented a remarkable way to boost the functionality of T Cell Engager proteins (TCE) by making tumor cells look more like an immune cell. The "engaged" T cells just LOVE the embrace. www.nature.com/articles/d43...
March 3, 2025 at 1:19 PM
A bit more #bioblue #biotech #oncology news from aletabiotherapeutics.com - we've invented a remarkable way to boost the functionality of T Cell Engager proteins (TCE) by making tumor cells look more like an immune cell. The "engaged" T cells just LOVE the embrace. www.nature.com/articles/d43...
hey #bioblue --- in a time of simply ridiculous copycat drug development we found a few examples of real innovation. Part 1 - novel bispecific therapeutics in oncology. Posted only at sugarconebiotech.com.
www.sugarconebiotech.com/insights/nov...
www.sugarconebiotech.com/insights/nov...
March 2, 2025 at 10:17 PM
hey #bioblue --- in a time of simply ridiculous copycat drug development we found a few examples of real innovation. Part 1 - novel bispecific therapeutics in oncology. Posted only at sugarconebiotech.com.
www.sugarconebiotech.com/insights/nov...
www.sugarconebiotech.com/insights/nov...
February 16, 2025 at 9:47 PM
sneak peak at the VEGF x PD(x) bispecific landscape: therapeutic designs
(report coming soon via sugarconebiotech.com)
(report coming soon via sugarconebiotech.com)
February 5, 2025 at 11:56 AM
sneak peak at the VEGF x PD(x) bispecific landscape: therapeutic designs
(report coming soon via sugarconebiotech.com)
(report coming soon via sugarconebiotech.com)
Well. Just finished and that was remarkable . And now I have to reread this before I can read Stella Maris.
Yikes what a gut punch this book became. #booksky
Yikes what a gut punch this book became. #booksky
January 29, 2025 at 1:17 PM
Well. Just finished and that was remarkable . And now I have to reread this before I can read Stella Maris.
Yikes what a gut punch this book became. #booksky
Yikes what a gut punch this book became. #booksky
We think that the copycat stampede in PD-1 x VEGF pathway bispecifics betrays weakness in innovation and ignores looming competition.
cc sugarconebiotech.com
cc sugarconebiotech.com
January 27, 2025 at 2:45 PM
We think that the copycat stampede in PD-1 x VEGF pathway bispecifics betrays weakness in innovation and ignores looming competition.
cc sugarconebiotech.com
cc sugarconebiotech.com
January 10, 2025 at 11:57 AM
When you're dictating because of chronic wrist tendinitis due to chronic PowerPoint production but the dog is staring at you:
"Do you wanna go out or you hungry which is it you gotta tell me I can’t read your flipping mind" is probably inappropriate in the middle of an invention disclosure
"Do you wanna go out or you hungry which is it you gotta tell me I can’t read your flipping mind" is probably inappropriate in the middle of an invention disclosure
January 8, 2025 at 9:10 PM
When you're dictating because of chronic wrist tendinitis due to chronic PowerPoint production but the dog is staring at you:
"Do you wanna go out or you hungry which is it you gotta tell me I can’t read your flipping mind" is probably inappropriate in the middle of an invention disclosure
"Do you wanna go out or you hungry which is it you gotta tell me I can’t read your flipping mind" is probably inappropriate in the middle of an invention disclosure
Very nice in vivo CAR T news from Esobiotec in the EU:
www.morningstar.com/news/globe-n...
disclosure: BOD member
www.morningstar.com/news/globe-n...
disclosure: BOD member
January 8, 2025 at 6:03 PM
Very nice in vivo CAR T news from Esobiotec in the EU:
www.morningstar.com/news/globe-n...
disclosure: BOD member
www.morningstar.com/news/globe-n...
disclosure: BOD member
Hello #Massachusetts! Been a lovely couple of days ... oh, seems unusually warm? Well, yup...
#climatecrisis #thinkglobal
#climatecrisis #thinkglobal
December 19, 2024 at 1:50 PM
Hello #Massachusetts! Been a lovely couple of days ... oh, seems unusually warm? Well, yup...
#climatecrisis #thinkglobal
#climatecrisis #thinkglobal